Abstract

Combination of Idasanutlin, Venetoclax and Obinutuzumab in Patients with Relapsed or Refractory (R/R) Non-Hodgkin Lymphoma (NHL): Results from a Phase I/II Study

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
Efficacy and Safety of Subcutaneous or Intravenous Administration of Rituximab in Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Final Results of the Randomized, Open-Label, Crossover, PrefMab Study
Mathias J Rummel ... Andrew Grigg
Blood | VOL. 130
Mathias J Rummel, et. al.Mathias J Rummel ... Andrew Grigg
25 Jun 2021
Bone Marrow Biopsy Impacts Response Assessment in a Minority of Patients with Follicular Lymphoma and Diffuse Large B-Cell Lymphoma Treated with Immunochemotherapy: Results from the Randomized Phase III GALLIUM and GOYA Trials
Sarah C Rutherford ... Peter Martin
Blood | VOL. 132
Sarah C Rutherford, et. al.Sarah C Rutherford ... Peter Martin
29 Nov 2018
Primary Analysis of the Tegar Study: A Phase II Study Exploring the Safety and Efficacy of Atezolizumab in Combination with Obinutuzumab or Rituximab in Patients with Relapsed or Refractory (R/R) Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), or Waldenstrom Macroglobulinemia (WM)
Panayiotis Panayiotidis ... Anastasios Stathis
Blood | VOL. 136
Panayiotis Panayiotidis, et. al.Panayiotis Panayiotidis ... Anastasios Stathis
05 Nov 2020
Circulating Tumor DNA Analysis Associates with Progression-Free Survival (PFS) with Odronextamab Monotherapy in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and Diffuse Large B-Cell Lymphoma (DLBCL): Identification of Minimal Residual Disease Status and High-Risk Subgroups from the Phase 2 ELM-2 Study
Jon E Arnason ... Vladimir Jankovic
Blood | VOL. 142
Jon E Arnason, et. al.Jon E Arnason ... Vladimir Jankovic
02 Nov 2023
View more papers

More From: Blood

Paper Title
Journal
Date
Author
New insights into the biology of T-cell lymphomas.
Javeed Iqbal ... Wing C Chan
Blood | VOL. -
Javeed Iqbal, et. al.Javeed Iqbal ... Wing C Chan
30 Aug 2024
Precision medicine may mitigate racial biases
Nada Hamad
Blood | VOL. 144
Nada HamadNada Hamad
29 Aug 2024
Circulating composite B- and T-cell lymphoma
Qianghua Zhou ... Hong Chang
Blood | VOL. 144
Qianghua Zhou, et. al.Qianghua Zhou ... Hong Chang
29 Aug 2024
SNPing away poor outcomes in T-ALL
Ryan J Summers ... David T Teachey
Blood | VOL. 144
Ryan J Summers, et. al.Ryan J Summers ... David T Teachey
29 Aug 2024
View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.